We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ventana ALK

News List

Roche Receives FDA approval for VENTANA ALK CDx Assay with LORBRENA americanpharmaceuticalreview
March 12, 2021
Roche announced US Food and Drug Administration (FDA) approval of the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with Pfizer's drug LORBRENA® ...
FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC americanpharmaceuticalreview
March 09, 2021
The U.S. Food and Drug Administration (FDA) has granted regular approval to lorlatinib (Lorbrena, Pfizer) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive ...